Our team

We are convinced that bringing academic and clinical research closer together is essential to accelerate innovations and meet patients’ real needs. That’s why, when we met ten years ago, we matched unmet medical needs with the development potential of our protein platform.

Following proof of concept validated in preclinical studies on ovarian cancer, we set up see2cure, a spin-off from the CNRS and the Claudius Regaud Oncopole, to bring our innovation into the human clinic and extend its scope to other cancers metastasising to the abdomen.